Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine

Figure 1 Change from baseline at week 48 in total hepatic hepatitis B virus DNA and hepatitis B virus covalently closed-circular DNA. ¹Adjusted for baseline total hepatic HBV DNA level; ²Adjusted for baseline hepatic cccDNA level. BL: Baseline; CI: Confidence interval; HGEq: Human genome equivalent; SE: Standard error; CccDNA: Covalently closed-circular DNA; ETV: Entecavir; LAM: Lamivudin.

Figure 2 Virologic, biochemical, and histologic efficacy at week 48 among treated patients with evaluable hepatic hepatitis B virus DNA pairs. ¹ALT < 1.25 × upper limit of normal; ²≥ 2-point decrease in Knodell necroinflammatory score with no worsening (≥ 1-point increase from baseline) of Knodell fibrosis score; ³≥ 1-point decrease in Ishak fibrosis score from baseline.